INAF

Terran Orbital’s Milani Satellite Delivered to the European Space Agency for Hera Mission

Retrieved on: 
Tuesday, March 19, 2024
Aerospace, Technology, Manufacturing, Satellite, Telecommunications, Nanotechnology, Networks, Defense, Contracts, Engineering, Mobile, Wireless, INAF, European Space Agency, DART, University of Helsinki, Motivation, University, ESA, International, Travel, Hera, Don Quixote, Tyvak, Science, Geology, Spacecraft, Dust, Australian Space Agency, CubeSat, HERA, VTT, Milani, Brno University of Technology, Mission, Multimedia, Asteroid

Tyvak International SRL (“Tyvak International”), a wholly-owned subsidiary of Terran Orbital Corporation (NYSE: LLAP ) and a leading European nano and microsatellite manufacturer based in Torino, Italy, today announced that they have completed the formal delivery of the Hera Milani satellite to the European Space Agency.

Key Points: 
  • Tyvak International SRL (“Tyvak International”), a wholly-owned subsidiary of Terran Orbital Corporation (NYSE: LLAP ) and a leading European nano and microsatellite manufacturer based in Torino, Italy, today announced that they have completed the formal delivery of the Hera Milani satellite to the European Space Agency.
  • View the full release here: https://www.businesswire.com/news/home/20240319935884/en/
    Ian Carnelli, Hera’s Project Manager for the European Space Agency attended the delivery event together with the Italian Space Agency, the Milani development team, and numerous local and international dignitaries.
  • Hera Milani is a nanosatellite funded by Italy and developed by Tyvak International for the European Space Agency, devoted to the visual inspection and dust detection of the Didymos asteroid following DART impact.
  • We are eager to see the spacecraft in action and help us unveil the many mysteries around the Didymos asteroid system.”
    The Italian Space Agency and European Space Agency decided to dedicate the Mission to Prof. Andrea Milani, who passed away in 2018.

Linearis Opened its New Laboratory Offering an AI Biomarkers Analytical Platform for Innovation Against Cancer, Diabetes, Antimicrobial Resistance, and Other Metabolic Diseases

Retrieved on: 
Tuesday, November 28, 2023
Université de Montréal, Press Conference (TV program), Mass spectrometry, AP-HP, IRIC, Université Laval, Acceleration, INAF, Medicago Inc., Biotechnology, DSM-IV codes, TMIC, Medicine, McGill University, Conference, Voltigeur, University, Drug discovery, FRQ, Cancer, Biomarker, AI, Diabetes, Metabolomics, University of Ottawa, Medical device, Pharmaceutical industry, Chomatodus, Operation Axe, Medicago

Leveraging artificial intelligence (AI), Linearis provides a comprehensive health status based on the analysis of 1,400 metabolomic biomarkers through mass spectrometry.

Key Points: 
  • Leveraging artificial intelligence (AI), Linearis provides a comprehensive health status based on the analysis of 1,400 metabolomic biomarkers through mass spectrometry.
  • The platform will enable its clients to improve prevention, screening, treatment monitoring, and new drug discovery.
  • The combination of AI and high-throughput automated analysis of 1,400 metabolomic biomarkers enables Linearis to better identify numerous elements associated with metabolic diseases including cancer, diabetes, and antimicrobial resistance.
  • "We are grateful for the support from Medicago during this transaction enabling the creation of this innovative and collaborative laboratory.

Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes

Retrieved on: 
Wednesday, November 8, 2023
INAF, Meal, Research, Trial of the century, Faculty, Fasting, Stomach, Peptide YY, Endocrine gland, Membrane protein, GIP, Human, Regulatory News Service, Université Laval, Hyperinsulinemia, Agonal respiration, PYY, Type 2 diabetes, Inflammation, Fibrinogen, Metabolism, Volunteering, Development, Glycated hemoglobin, Phase, Prediabetes, Food court, Lipid, Disease, Risk, Plant, Medicine, Research and development, Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Medical school, Industrial Affairs Committee (Iceland), Partnership, Sensation, Blood, Nutrition, Hormone, CET, Safety, Insulin resistance, Overweight, Gastric inhibitory polypeptide, Glucose, Insulin, Pharmaceutical industry, Dietary supplement, Medical device, Animal feed

Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes

Key Points: 
  • Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The study confirms TOTUM•63's efficacy results, in particular the lasting reduction in glycated hemoglobin, one of the main markers of prediabetes and type 2 diabetes.
  • It demonstrates TOTUM•63's multi-target mode of action in subjects at risk, improving the efficacy of energy metabolism, particularly after meals.
  • Mode of action clinical results: TOTUM•63 regulates energy metabolism
    In addition to the positive clinical efficacy studies already conducted, the mode of action study was carried out on 19 overweight or obese volunteers at risk of developing type 2 diabetes.

Valbiotis announces its roadmap and strategic priorities on the eve of key milestones for its portfolio of innovative active substances

Retrieved on: 
Wednesday, July 12, 2023
Volunteering, Communication, Business development, Partnership, Marketing, Pharmacy, Triglyceride, INAF, Business, Research and development, Hypercholesterolemia, Development, Patient, LDL, Regulatory News Service, Entrepreneurship, Research, Phase, Prediabetes, Pharmaceutical industry, Vaccine, Fine chemical

As a reminder, this international, multicenter, randomized, placebo-controlled study was carried out in a population of 636 volunteers with prediabetes and early-stage, untreated type 2 diabetes.

Key Points: 
  • As a reminder, this international, multicenter, randomized, placebo-controlled study was carried out in a population of 636 volunteers with prediabetes and early-stage, untreated type 2 diabetes.
  • The Company is preparing a final Phase II/III clinical stage, which will provide the clinical data required to file a health claim.
  • On the industrial processes front, Valbiotis is continuing to set up the supply chain, from sourcing plant raw materials through to marketing.
  • The sales timetable in France has thus been confirmed, with TOTUM•070 due for launch in the first half of 2024.

Valbiotis Publishes Its 2022 Annual Results and Provides an Update on Its Strategic Roadmap

Retrieved on: 
Wednesday, March 15, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Fitness & Nutrition, Clinical Trials, United Nations Global Compact, Statutory auditor, Corporate social responsibility, ISO, PEA, Risk, AASLD, Partnership, Prediabetes, Research and development, Liver, Dyslipidemia, LDL, Université Laval, NASH, NAFL, Hypercholesterolemia, Phase, Patient, Type 2 diabetes, ASM Clermont Auvergne, De novo, Hepatology, INAF, CHF, INSIGHT, American Association of Clinical Endocrinologists, Development, Marketing, CSR, Volunteering, ANR, University, Food court, R, Pharmaceutical industry, Cryptocurrency

Sébastien PELTIER, Chairman of the Board of Directors at Valbiotis, comments: "During the year 2022, Valbiotis continued to pursue its R&D roadmap while providing itself with the means to accelerate its commercial strategy.

Key Points: 
  • Sébastien PELTIER, Chairman of the Board of Directors at Valbiotis, comments: "During the year 2022, Valbiotis continued to pursue its R&D roadmap while providing itself with the means to accelerate its commercial strategy.
  • The year 2022 was marked by the positive results of the Phase II HEART study, announced in June ( press release of June 13, 2022 ).
  • Regarding TOTUM•854, Valbiotis launched the Phase II/III INSIGHT and INSIGHT 2 clinical studies in early 2022 ( press release of February 17, 2022 ).
  • At the beginning of 2022, Valbiotis updated the development strategy for TOTUM•448 ( press release of January 6, 2022 ).

TEXAS-DEVELOPED PATENT-FREE COVID-19 VACCINE TECHNOLOGY RECEIVES EMERGENCY USE AUTHORIZATION IN INDONESIA

Retrieved on: 
Friday, September 30, 2022
Certification, Bio Farma, Health, Baylor, HMO, COVID-19, Tropical medicine, Twitter, Jan, KAEF, Hospital, Pediatrics, Texas Children's Hospital, Kings County Hospital Center, View, News, Halal certification in the Philippines, Baylor University, Partnership HealthPlan of California, Vaccine, Baylor College of Medicine, INAF, Research, Pharmacy, National school, CVD, Multimedia, Urgent care center, Education, Pharmaceutical industry, Woman

Itreceived emergency use authorization in Indonesia, as a primary vaccine in adults.

Key Points: 
  • Itreceived emergency use authorization in Indonesia, as a primary vaccine in adults.
  • Indonesia is seeking Halal Certification for the vaccine since no animal cells or products were used in the production of the vaccine.
  • The pharmaceutical company is currently manufacturing Covid-19 primary series vaccine, while booster vaccine is in the clinical trial stage and soon followed by vaccine for children.
  • Bio Farma became a holding company after a merger of three listed state-owned pharmaceutical companies in Indonesia.

 Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022

Retrieved on: 
Thursday, September 15, 2022
Biotechnology, Pharmaceutical, Health, Institute, Mission statement, Prediabetes, Degenerative disease, Volunteering, Health, IFRS, Time, United Nations Global Compact, De novo, ESG, Hypercholesterolemia, Development, LDL, Statutory auditor, Director, Risk, Corporate social responsibility, Phase, Research, NASH, Small, Nutrition, Russell Midcap Index, Company, Population, Pernod Ricard, Review, Non-alcoholic fatty liver disease, Partnership, CSR, Food science, Environment, Program, Star Trek: Phase II, Physician, Université Laval, Triglyceride, Research and development, Liver, Board, Christofle, INAF, Marketing, Awareness, ISO, Dysglycemia, INSIGHT, Pharmaceutical industry, Dietary supplement

In July 2022, Valbiotis announced the end of recruitment with the randomization of the last of the 600 participating volunteers ( press release of July 28, 2022 ).

Key Points: 
  • In July 2022, Valbiotis announced the end of recruitment with the randomization of the last of the 600 participating volunteers ( press release of July 28, 2022 ).
  • In February 2022, Valbiotis received approval to initiate two Phase II/III clinical trials, INSIGHT and INSIGHT 2 ( press release of February 17, 2022 ).
  • The Company's interim financial statements, prepared in accordance with IFRS, were approved by the Board of Directors on September 7, 2022.
  • They have been subject to a limited review by the Statutory Auditor and are available on the Valbiotis website: www.valbiotis.com (investors section).

Tyvak International, a Terran Orbital Company, Completes Critical Design Review of Deep Space Bound Milani Satellite

Retrieved on: 
Tuesday, June 21, 2022
Technology, Other Defense, Contracts, Satellite, Telecommunications, Aerospace, Nanotechnology, Manufacturing, Data Management, Defense, Solution, VISTA, Water, INAF, VTT, DART, Design review (U.S. government), HERA, Didymos, ESA, Australian Space Agency, Volatility, LLAP, Miniaturization, Orbital, European Space Agency, Acquisition, Asteroid, Milani, Sunlight, Hera, University, Moonlet, INFN, Multimedia, NYSE, Orbital Corporation, Communications satellite, Dimorphos

Terran Orbital Corporation (NYSE: LLAP ), a global leader in satellite solutions, primarily serving the aerospace and defense industries, today announced its wholly-owned subsidiary, Tyvak International SRL, has together with its partners, achieved full Critical Design Review of the Milani spacecraft.

Key Points: 
  • Terran Orbital Corporation (NYSE: LLAP ), a global leader in satellite solutions, primarily serving the aerospace and defense industries, today announced its wholly-owned subsidiary, Tyvak International SRL, has together with its partners, achieved full Critical Design Review of the Milani spacecraft.
  • A critical component of the Hera planetary defense mission, Milani will be the European Space Agencys (ESA) first deep-space nanosatellite.
  • Tyvak Internationals design and construction of the Milani spacecraft will enable the acquisition of extremely valuable information for future asteroid deflection missions.
  • Tyvak International, a Terran Orbital Corporation, is a leading European nano and microsatellite provider, based in Torino, Italy.

Valbiotis Announces the First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Conducted by the INAF1, in Partnership With Nestlé Health Science

Retrieved on: 
Thursday, April 28, 2022
Clinical Trials, Cardiology, Other Natural Resources, Other Health, Biotechnology, Pharmaceutical, Health, Natural Resources, Science, Other Science, Metabolomics, Health Canada, Overweight, Investor, Ministry of Health, Nutrition and Indigenous Medicine, BPI, Prediabetes, Social, Risk, Health, Human, Director, Research, Union, Nutrition, Company, Hormone, Industrial Affairs Committee (Iceland), Volunteering, Lists of diseases, CEO, Waist, AMF, Incretin, Partnership, University, ERDF, INAF, Board, Food science, Research and development, European Regional Development Fund, Degenerative disease, Acceleration, Development, Inflammation, Pharmaceutical industry, Management, Health insurance, Medical device, Medicine

These data will complement the efficacy data from the pivotal Phase II/III REVERSE-IT clinical trial, which is currently underway.

Key Points: 
  • These data will complement the efficacy data from the pivotal Phase II/III REVERSE-IT clinical trial, which is currently underway.
  • We are excited to enter this final push into the prediabetes market and thank the INAF and our partner Nestl Health Science for their involvement right alongside us."
  • The TOTUM63 clinical mode of action study will explore the main hypotheses of the mode of action in humans established thanks to the results of preclinical work.
  • In February 2020, Valbiotis signed a long-term global strategic partnership with Nestl Health Science for the development and worldwide commercialization of TOTUM63.

COVID-19: Tannic acid targets key stages in the fight against SARS-CoV-2 infection

Retrieved on: 
Wednesday, March 9, 2022
Varennes-en-Argonne, QC, Tea, MONTRAL, Enzyme, Tablet, International Journal of Molecular Sciences, INAF, Research, Engineering, RBD, Cell, Polyphenol, Tannin, La Trobe Institute for Molecular Science, Institut national de la recherche scientifique, Institute, Alpha, Drink, ACE2, Toxicity, Canadian International Council, Investor, Interdisciplinarity, TMPRSS2, UQAM, Natural science, Severe acute respiratory syndrome coronavirus 2, McGill University, Protein, Student, NSERC, INRS, Vaccine, Pharmaceutical industry, Nature, Universite des Sciences Appliquée et Management

"Tannic acid binds to the RBD protein and prevents it from binding to the ACE2 receptor," said Professor Ramassamy.

Key Points: 
  • "Tannic acid binds to the RBD protein and prevents it from binding to the ACE2 receptor," said Professor Ramassamy.
  • His team further investigated the effects of tannic acid on other key mechanisms involved in SARS-CoV-2 infection downstream of the RBD-ACE2 bond.
  • Tannic acid is a natural polyphenol found in many beverages such as red wine or tea, but in much lower quantities.
  • Although they contain tannins, their consumption would not have any protective effects because of their low concentration of tannic acid.